Table 1.
Demographics and baseline characteristics of study participants at enrolment.
| Group 1 TCV + IPV (delayed MCV-A) |
Group 2 TCV + MCV-A |
Group 3 MCV-A + IPV |
|
|---|---|---|---|
| Enrolled | 49 | 51 | 51 |
| Vaccinated | 49 | 50 | 51 |
| Sex | |||
| Female | 19 (38.8%) | 23 (46.0%) | 31 (60.8%) |
| Male | 30 (61.2%) | 27 (54.0%) | 20 (39.2%) |
| Age (months) | 16.4 ± 1.7 | 16.1 ± 1.7 | 15.7 ± 1.2 |
| Baseline meningococcal A SBA titre (≥4) | NA | 24 (48.0%) | 10 (19.6%) |
| Baseline Vi titre (≥7.4 EU/mL) | 7 (14.3%) | 5 (10.0%) | 6 (11.8%) |
| Baseline tetanus titre (≥0.001 IU/mL) | 47 (96.0%) | 50 (100%) | 51 (100%) |
| Baseline malaria positive | 2 (4.1%) | 1 (2.0%) | 0 (0%) |
Data are n (%) or mean ± standard deviation. n = number of participants. EU, ELISA units; IPV, inactivated polio vaccine; IU, international units; MCV-A, group A meningococcal conjugate vaccine; NA, not applicable; SBA, serum bactericidal antibody; TCV, typhoid conjugate vaccine.